Myasthenia gravis following dabrafenib and trametinib for metastatic melanoma

Neurology. 2020 Feb 18;94(7):322-323. doi: 10.1212/WNL.0000000000008860. Epub 2019 Dec 30.

Authors

Austin Zaloum¹, Jean-Pierre René Falet², Arielle Elkrief², Colin Chalk²

Affiliations

¹ From the Departments of Neurology and Neurosurgery (A.Z., J.-P.R.F., C.C.) and Oncology (A.E.), McGill University, Montreal, Canada. austin.zaloum@mail.mcgill.ca.
² From the Departments of Neurology and Neurosurgery (A.Z., J.-P.R.F., C.C.) and Oncology (A.E.), McGill University, Montreal, Canada.

PMID: 31888971
DOI: 10.1212/WNL.0000000000008860

No abstract available

Publication types

Case Reports

MeSH terms

Aged
Antineoplastic Agents / adverse effects
Antineoplastic Agents / therapeutic use*
Humans
Imidazoles / adverse effects
Imidazoles / therapeutic use*
Male
Melanoma / drug therapy*
Melanoma / genetics
Myasthenia Gravis / etiology*
Neoplasm Metastasis / drug therapy
Neoplasm Metastasis / genetics
Oximes / adverse effects
Oximes / therapeutic use*
Protein Kinase Inhibitors / adverse effects
Protein Kinase Inhibitors / therapeutic use
Pyridones / adverse effects
Pyridones / therapeutic use*
Pyrimidinones / adverse effects
Pyrimidinones / therapeutic use*
Scalp
Skin Neoplasms / drug therapy*
Skin Neoplasms / genetics

Substances

Antineoplastic Agents
Imidazoles
Oximes
Protein Kinase Inhibitors
Pyridones
Pyrimidinones
trametinib
dabrafenib